We attempted to block CD36 and detect changes in CD8+ T cell function, after employment of SSO, the cytotoxic function of CD36+CD8+ T cells was partially restored without altering the immune checkpoints, which indicated the potential of CD36 as a therapeutic target for NSCLC. This evidence concerns the gene CD8A and non-small cell lung carcinoma.